期刊文献+

自体造血干细胞移植治疗血液系统恶性肿瘤过程中CSA诱导的GVHD 被引量:3

Induction of GVHD by CSA in patients undergoing autologous hematopoietic stem cell transplantation for hematological malignancies
原文传递
导出
摘要 目的 :研究自体造血干细胞移植治疗血液系统恶性肿瘤过程中环孢素A(CSA)能否诱导移植物抗宿主病(GVHD) ,并确定其毒副反应。方法 :进行自体造血干细胞移植的 10例血液系统恶性肿瘤患者接受CSA静脉滴注1.5mg/ (kg·d) ,0~ 2 8d ,观察皮疹情况、有无腹泻及血清胆红素水平来判断GVHD的发生 ;同时观察移植后造血重建、感染、出血以及检测肝、肾功能来分析其治疗的毒副反应。结果 :2例次早期出现GVHD ,皮疹为 +和 + + ,出现时间分别为移植后 8和 17d ,持续时间较短 ( 4和 5d) ,外周血WBC计数分别为 0 .9× 10 9/L和 0 .2× 10 9/L ;6例次患者出现GVHD皮疹 ( 1例 + ,5例 + + ,不包括前述 2例次 )的时间为 30d( 2 2~ 4 4d) ,皮疹持续时间为 18d( 9~ 2 8d) ,外周血WBC计数为 1.4 5× 10 9/L[( 0 .4~ 2 .6 )× 10 9/L]。对移植后造血重建、感染、出血 ,以及肝、肾功能的影响不明显。结论 :CSA在自体造血干细胞移植过程中可以安全地诱导GVHD的发生 。 Objective:To investigate if graft_ versus _host disease(GVHD) could be induced by treatment with cyclosporine A(CSA) in patients undergoing autologous hematopoietic stem cell transplantation for hematological malignancies, and define the toxicities of this approach. Methods: Ten cases of hematological malignancies were administrated with intravenous CSA 1.5?mg/(kg·d) 0-28?d following autologous stem cell transplantation.Induction of GVHD was monitored by rashes, diarrhea and jaundice.Toxicities of treatment were assessed by analysis of hematopoietic reconstitution, infection, hemorrhage, hepatic and renal function after_transplantation. Results:GVHD was early induced in 2 cases at 8d and 17?d after transplantation respectively; Rashes were graded + and ++, lasted 4 and 5?d; WBC counts were 0.9×10 9/L and 0.2×10 9/L at onset of GVHD. GVHD of the skin occurred in 6 cases except 2 cases mentioned above(1 case +, 5 cases ++) at 30?d(22-44?d) and lasted 18?d(9- 28?d) ; WBC counts were 1.45×10 9/L[(0.4-2.6)×10 9/L] at onset of GVHD. No negative impact on hematopoietic reconstitution, infection, hemorrhage, hepatic and renal function after transplantation was observed.Conclusions:GVHD can be safely induced by treatment with CSA in patients undergoing autologous hematopoietic stem cell transplantation for hematological malignancies. Further investigation is needed for evidence of antitumor efficacy.
出处 《军事医学科学院院刊》 CSCD 北大核心 2003年第2期128-130,共3页 Bulletin of the Academy of Military Medical Sciences
关键词 血液系统恶性肿瘤 自体造血干细胞移植 环孢素A 移植物抗宿主病 毒副反应 autologous hematopoietic stem cell transplantation hematologic neoplasms cyclosporine graft_ versus _host disease
  • 相关文献

参考文献9

  • 1高春记,楼方定,姚善谦,刘海川,朱军,周绮,孟凡义,韩晓萍,王小沛.自体造血干细胞移植后造血功能重建的影响因素[J].中华血液学杂志,1994,15(10):538-539. 被引量:2
  • 2张伯龙,黄文荣,达万明,张占强,姚善谦,高春记,韩晓萍,吴晓雄,王全顺,于力,张苗,靳海杰.双次自体造血干细胞移植治疗恶性血液病的临床分析[J].中华医学杂志,2002,82(2):123-126. 被引量:3
  • 3Weiden PL, Sullivan KM, Fluornoy N, et al. Antileukemic effect of graft versus host disease. Contribution to improved survival after allogeneic marrow transplantation [ J ]. N Engl J Med, 1980, 304 ( 25 ) :1529- 1533.
  • 4Jones RJ, Vogelsang GB, Hess AD, et al. Induction of graft-versushost disease after autologous bone marrow transplantation[J]. Lancet,1989,1(8641) :754 - 757.
  • 5Kennedy MJ, Vogelsang GB, Beveridge RA, et ol. Phase I trial intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer[J]. J Clin Oncol, 1993,11 (3) :478 - 484.
  • 6Weiden PL, Sullivan KM, Fluornoy N, et al. Antileukemic effect of graft-versts-host disease in human recipients of allogeneic-marrow grafts[J]. N Engl J Med, 1979,300(19) : 1068 - 1073.
  • 7Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants[J]. Science,2002,295(5562) :2097 - 2100.
  • 8Carella AM, Gaozza E, Congiu A, et al. Cyclosporine-induced graftversts-host disease after autologous bone marrow transplantation in hematological malignancies[J]. Ann Hematol, 1991,62(5) : 156- 159.
  • 9Yeager AM, Vogelsang GB, Jones R J, et al. Induction of cutaneous graft-versus-host reaction by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia [ J ]. Blood, 1992,79 ( 11 ) : 3031 - 3035.

二级参考文献5

  • 1Dick KA, Spitzer G. Evaluation of the use of high dose cytoreduction with autolo gous marrow rescue in various maliglancies. Transplantation,1986,41: 4-20.
  • 2Powles R, Mehta J, Singhal S, et al. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemothrapy f or adult acute lymphoblastic leukemia in first remission: 50 cases from a single center. Bone Marrow Transplantation,1995,16:241-247.
  • 3Reiffer s J, Labopin M, Sans M, et al. Autologous blood cell vs marrow transplantation f or acute myeloid leukemia in complete remission: an EBMT retrospective analysis. Bone Marrow Transplantation,2000,26:1115-1119.
  • 4Rowlings PA. 1996 summary slides show current use and outcome o f blood and marrow transplantation. Atologous transplant Registry-North America ABMTR Newsletter, 1996,3: 6-12.
  • 5De LRJ, Sanz GF, Martin G, e t al. Autologous bone marrow transplantation for patients with acute myeloblasti c leukemia in relapse after autologous blood stem cell transplantation. Bone-Ma rrow-Transplant, 1996, 18: 1167-1173.

共引文献3

同被引文献13

  • 1Grateolh A.Activity survey and historical perspective of autologous stem cell transplantation in Europe.Semin Hematol,2007,44:220-226.
  • 2Jaffe ES,Harris NL,Stein H,et al.Pathology and genetics of tumours of haematopoietic and lymphoid tissues.IARC Press: Lyon2001
  • 3Bhaduri S,Kubanek B,Heit W,et al.A case of preleukemia-reconstitution of normal marrow function after bone marrow transplantation (BMT) from identical twin.Blut,1979; 38:145- 149
  • 4Anderson JE,Anasetti C,Appelbaum FR,et al.Unrelated donor marrow transplantation for myelodysplastic syndrome (MDS) and MDS-related acute myeloid leukaemia.Br J Hematol,1996; 93: 59-67
  • 5Deeg HJ,Shulman HM,Anderson JE,et al.Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.Blood,2000; 95:1188- 1894
  • 6Dini G,Cancedda R,Locatelli F,et al.Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Transplant Group (GITMO).Haematologica,2000; 85(suppl11) :30 - 36
  • 7Petersdorf EW,Gooley TA,Anasetti C,et al.Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class Ⅰ and Ⅱ alleles in the donor and recipient.Blood,1998; 92:3515 - 3520
  • 8Beatty PG,Hansen JA,Thomas ED,et al.Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies.Transplantation,1991; 2:443 - 447
  • 9Peterdorf EW,Longton GM,Anasetti C,et al.The significance of HLA-DRB1 matching on clinical outcome after HLA-A,B,DRidentical unrelated donor marrow transplantation.Blood,1995; 86:1606 - 1613
  • 10Hansen JA,Gooley TA,Martin PJ,et al.Bone marrow transplantation from unrelated donors for patients with chronic myeloid leukemia.N Eng J Med,1998; 338:962 -968

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部